Clinical Trials Browser

Unknown × Advanced Solid Tumors × sintilimab × Clear all

NCT05164458 2023-12-28

Safety and Efficacy of IBI389 Single Agent, and in Combination With Sintilimab, in Patients With Advanced Malignancies

Phase 1 Unknown

Other solid neoplasm

Advanced Solid Tumors